Novo Nordisk (NVO) Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
NVO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 198.00 |
| 52 Week High | DKK 292.25 |
| 52 Week Low | DKK 166.40 |
| Beta | 0.32 |
| 1 Month Change | 6.45% |
| 3 Month Change | -32.25% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -24.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVO | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -6.1% | -2.8% | 1.5% |
| 1Y | n/a | -24.9% | 21.2% |
Return vs Industry: Insufficient data to determine how NVO performed against the Polish Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NVO performed against the Polish Market.
Price Volatility
| NVO volatility | |
|---|---|
| NVO Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in PL Market | 9.8% |
| 10% least volatile stocks in PL Market | 2.9% |
Stable Share Price: NVO's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: Insufficient data to determine NVO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 78,387 | Maziar Doustdar | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NVO fundamental statistics | |
|---|---|
| Market cap | zł885.95b |
| Earnings (TTM) | zł63.27b |
| Revenue (TTM) | zł177.70b |
Is NVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVO income statement (TTM) | |
|---|---|
| Revenue | DKK 311.94b |
| Cost of Revenue | DKK 49.11b |
| Gross Profit | DKK 262.83b |
| Other Expenses | DKK 151.76b |
| Earnings | DKK 111.07b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | 25.00 |
| Gross Margin | 84.26% |
| Net Profit Margin | 35.61% |
| Debt/Equity Ratio | 59.1% |
How did NVO perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/08 18:44 |
| End of Day Share Price | 2025/09/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novo Nordisk A/S is covered by 73 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |